Using light to convert racemic mixtures into pure enantiomers
Photoredox-enabled deracemization: method development and mechanistic studies
['FUNDING_FELLOWSHIP'] · PRINCETON UNIVERSITY · NIH-10899023
This study is exploring a new way to use light to turn mixtures of two similar chemical forms into just one pure form, which could help make better medicines for patients.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PRINCETON UNIVERSITY (nih funded) |
| Locations | 1 site (Princeton, UNITED STATES) |
| Trial ID | NIH-10899023 on ClinicalTrials.gov |
What this research studies
This research investigates a novel method to convert racemic mixtures, which contain equal amounts of two enantiomers, into enantiopure compounds using light. By employing a photocatalytic strategy, the study aims to overcome the thermodynamic and kinetic challenges typically associated with deracemization reactions. Patients may benefit from this research as it focuses on improving the synthesis of pharmaceutical compounds that are crucial for effective medication. The approach involves manipulating the energy barriers of chemical reactions to favor the formation of one enantiomer over the other, potentially leading to more effective drugs.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would be individuals requiring medications that are enantiomer-specific for optimal therapeutic effects.
Not a fit: Patients who do not require enantiomer-specific medications or those with conditions unrelated to the pharmaceutical compounds being studied may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and targeted medications by enabling the production of pure enantiomers from racemic mixtures.
How similar studies have performed: While deracemization methods are challenging, the use of light-driven processes in chemical reactions has shown promise in other studies, indicating potential for success in this novel approach.
Where this research is happening
Princeton, UNITED STATES
- PRINCETON UNIVERSITY — Princeton, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, JUSTIN — PRINCETON UNIVERSITY
- Study coordinator: WANG, JUSTIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.